



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

21 May 2026  
EMADOC-1700519818-2790091  
Committee for Medicinal Products for Human Use (CHMP)

## Summary of opinion<sup>1</sup> (post authorisation)

---

### Wegovy semaglutide

On 21 May 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Wegovy. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S.

The CHMP adopted a new pharmaceutical form associated with a new route of administration, tablets for oral use, in four new strengths (1.5 mg, 4 mg, 9 mg and 25 mg).

The full indications for Wegovy tablets for oral use will be as follows:

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

- $\geq 30 \text{ kg/m}^2$  (obesity), or
- $\geq 27 \text{ kg/m}^2$  to  $< 30 \text{ kg/m}^2$  (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

For trial results with respect to populations studied, see section 5.1.

The indications for Wegovy solution for injection in pre-filled pens remain unchanged and are available in the summary of product characteristics (SmPC).

Detailed recommendations for the use of this product will be described in the updated SmPC, which will be published on EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

---

<sup>1</sup> Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

